Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
AIDS
    May 2024
  1. SALTO JN, Volkow P, Herrera-Goepfert R, Lopez-Garcia AI, et al
    Unmasked Kaposi and sarcoidosis immune reconstitution inflammatory syndrome in a patient with AIDS.
    AIDS. 2024;38:933-934.
    >> Share

    March 2024
  2. WIJSTMA ES, Jongen VW, Boyd A, van den Elshout M, et al
    Concordance between daily diary reported PrEP intake and intraerythrocytic tenofovir diphosphate (TFV-DP) in the Amsterdam PrEP demonstration project.
    AIDS. 2024 Mar 21. doi: 10.1097/QAD.0000000000003889.
    >> Share

  3. MIGISHA R, Chen G, Muyindike WR, Aung TN, et al
    Regional variation in weight change after the transition to dolutegravir: a prospective cohort study in Uganda and South Africa.
    AIDS. 2024 Mar 20. doi: 10.1097/QAD.0000000000003888.
    >> Share

  4. DICKSON S, James K
    Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance.
    AIDS. 2024;38:610-612.
    >> Share

  5. DADABHAI S, Chou VB, Pinilla M, Chinula L, et al
    Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial.
    AIDS. 2024 Mar 4. doi: 10.1097/QAD.0000000000003878.
    >> Share

    February 2024
  6. SHIVAKOTI R, Giganti MJ, Lederman MM, Ketchum R, et al
    Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery.
    AIDS. 2024 Feb 26. doi: 10.1097/QAD.0000000000003877.
    >> Share

  7. ORKIN C, Antinori A, Rockstroh JK, Moreno-Guillen S, et al
    Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy: 96-week pooled analysis.
    AIDS. 2024 Feb 12. doi: 10.1097/QAD.0000000000003865.
    >> Share

    January 2024
  8. VAN DER WEKKEN-PAS L, Nassiwa S, Malaba T, Lamorde M, et al
    Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.
    AIDS. 2024 Jan 26. doi: 10.1097/QAD.0000000000003852.
    >> Share

  9. CATTANEO D, Pagano S, Colombo ML, Giacomelli A, et al
    Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens.
    AIDS. 2024 Jan 16. doi: 10.1097/QAD.0000000000003843.
    >> Share

    December 2023
  10. THORNHILL JP, Fox J, Martin GE, Hall R, et al
    Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
    AIDS. 2023 Dec 21. doi: 10.1097/QAD.0000000000003825.
    >> Share

  11. DORWARD J, Govender K, Moodley P, Lessells R, et al
    Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy.
    AIDS. 2023 Dec 19. doi: 10.1097/QAD.0000000000003818.
    >> Share

  12. MOORE AEB, Burns JE, Sally D, Milinkovic A, et al
    Bone turnover change after randomised switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
    AIDS. 2023 Dec 7. doi: 10.1097/QAD.0000000000003811.
    >> Share

    November 2023
  13. CHERKOS AS, Cranmer LM, Njuguna I, LaCourse SM, et al
    Effect of TB-HIV co-treatment on clinical and growth outcomes among hospitalized children newly initiating antiretroviral therapy.
    AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003797.
    >> Share

  14. HOLDEN CJ, Lampe FC, Burns FM, Chaloner C, et al
    Association of age at ART initiation with CD4:CD8 ratio recovery among virally suppressed people living with HIV, 2001-2019.
    AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003801.
    >> Share

  15. GREGSON CL, Rehman AM, Rukuni R, Mukwasi-Kahari C, et al
    Perinatal HIV infection is associated with deficits in muscle function in children and adolescents: a cross-sectional study in Zimbabwe.
    AIDS. 2023 Nov 22. doi: 10.1097/QAD.0000000000003795.
    >> Share

  16. WILLIAMS PL, Karalius B, Patel K, Aschengrau A, et al
    Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens.
    AIDS. 2023 Nov 22. doi: 10.1097/QAD.0000000000003796.
    >> Share

  17. CHAWKI S, Goldwirt L, Mouhebb ME, Gabassi A, et al
    Ex vivo rectal tissue infection with HIV-1 to assess time to protection following oral PrEP with TDF/FTC (a sub-study of the ANRS PREVENIR study).
    AIDS. 2023 Nov 16. doi: 10.1097/QAD.0000000000003789.
    >> Share

  18. LANTZ AM, Cottrell ML, Corbett AH, Chinula L, et al
    Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
    AIDS. 2023;37:2185-2190.
    >> Share

  19. FILIP I
    The steep cost of HIV treatment interruptions.
    AIDS. 2023;37:N17.
    >> Share

  20. SILVERBERG MJ, Pimentel N, Leyden WA, Leong TK, et al
    Initial antiretroviral therapy regimen and risk of heart failure.
    AIDS. 2023 Nov 14. doi: 10.1097/QAD.0000000000003786.
    >> Share

  21. ZHANG H, Hindman JT, Lin L, Davis M, et al
    A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.
    AIDS. 2023 Nov 8. doi: 10.1097/QAD.0000000000003783.
    >> Share

  22. FRANCOIS K, Van Onacker JD, Jordan MR, Journel I, et al
    First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
    AIDS. 2023;37:2097-2099.
    >> Share

  23. BREW BJ, Clifford DB
    Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?
    AIDS. 2023;37:2095-2096.
    >> Share

    October 2023
  24. LARTEY M, Ganu VJ, Tachi K, Yang H, et al
    Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and HBV viral suppression.
    AIDS. 2023 Oct 20. doi: 10.1097/QAD.0000000000003764.
    >> Share

  25. WANG Y, Wu G, Wen Z, Lei H, et al
    HAART-related effects on morphological connectivity in HIV: an individual-level morphological brain network study.
    AIDS. 2023 Oct 20. doi: 10.1097/QAD.0000000000003759.
    >> Share

  26. BHATTACHARYA D, Guo R, Tseng CH, Emel L, et al
    Hepatitis B virus clinical and virologic characteristics in an HIV perinatal transmission study in sub-saharan Africa, HPTN 046- a post-hoc analysis.
    AIDS. 2023 Oct 18. doi: 10.1097/QAD.0000000000003752.
    >> Share

  27. MPEBE GGA, Phinius BB, Mutenga S, Baruti K, et al
    Hepatitis B surface antigen loss in chronic hepatitis B virus and HIV-1 Co-Infections individuals in Botswana.
    AIDS. 2023 Oct 16. doi: 10.1097/QAD.0000000000003753.
    >> Share

    September 2023
  28. PARRA-RODRIGUEZ L, O'halloran J, Wang Y, Jin W, et al
    Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003730.
    >> Share

  29. DAVEY DLJ, Nyemba DC, Mvududu R, Mashele N, et al
    Pregnancy outcomes following self-reported and objective-measured exposure to oral preexposure prophylaxis in South Africa: an observational cohort study.
    AIDS. 2023 Sep 18. doi: 10.1097/QAD.0000000000003729.
    >> Share

  30. MUSTANSKI B, Ryan DT, Spinelli MA, Gandhi M, et al
    Urine point-Of-care tenofovir test demonstrates strong predictive clinical and research utility.
    AIDS. 2023 Sep 6. doi: 10.1097/QAD.0000000000003710.
    >> Share

  31. CHEN RQ, Zino L, Geerlings S, Colbers A, et al
    Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
    AIDS. 2023;37:1769-1771.
    >> Share

    August 2023
  32. PERAZZOLO S, Stephen Z, Eguchi M, Xu X, et al
    A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable.
    AIDS. 2023 Aug 25. doi: 10.1097/QAD.0000000000003706.
    >> Share

  33. BENGTSON AM, Madlala H, Matjila MJ, Levitt N, et al
    Associations of HIV and antiretroviral therapy with gestational diabetes: findings from a prospective cohort in South Africa.
    AIDS. 2023 Aug 3. doi: 10.1097/QAD.0000000000003678.
    >> Share

    July 2023
  34. VERBURGH ML, van der Valk M, Rijnders BJA, Reiss P, et al
    No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands.
    AIDS. 2023;37:1481-1486.
    >> Share

  35. PALICH R, Hentzien M, Hocqueloux L, Duvivier C, et al
    Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people living with HIV in France.
    AIDS. 2023 Jul 14. doi: 10.1097/QAD.0000000000003657.
    >> Share

  36. VERBURGH ML, Wit FWNM, Boyd A, Reiss P, et al
    No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
    AIDS. 2023 Jul 11. doi: 10.1097/QAD.0000000000003654.
    >> Share

  37. SHIKUMA CM, Wojna V, De Gruttola V, Siriwardhana C, et al
    Impact of ART intensification with CCR5 antagonist maraviroc on HIV-associated neurocognitive impairment.
    AIDS. 2023 Jul 7. doi: 10.1097/QAD.0000000000003650.
    >> Share

  38. HAZRA A, Landovitz RJ, Marzinke MA, Quinby C, et al
    Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis.
    AIDS. 2023 Jul 4. doi: 10.1097/QAD.0000000000003644.
    >> Share

  39. DIETRICH DK, Laidlaw E, Hammoud DA, Pau AK, et al
    Dramatic Improvement of MRI Abnormalities of HIV Encephalopathy after Suppressive Antiretroviral Therapy.
    AIDS. 2023;37:1339-1340.
    >> Share

    June 2023
  40. PINTYE J, Kinuthia J, Abuna F, Anderson PL, et al
    PrEP initiation, persistence, and adherence during pregnancy through the postpartum period: a prospective analysis in Kenya.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003617.
    >> Share

  41. SMITH C, Silveira L, Crotteau M, Garth K, et al
    Modern antiretroviral regimens in pregnant women: virologic outcomes and durability.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003616.
    >> Share

  42. RAMETSE CL, Webb EL, Herrera C, Alinde B, et al
    A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003619.
    >> Share

  43. BARTHOLD D, Saldarriaga EM, Brah AT, Hauber B, et al
    Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003620.
    >> Share

  44. WARNER NC, Shishido A, Fulco PP, Sastry S, et al
    Immune reconstitution inflammatory syndrome due to monkeypox in two patients with AIDS.
    AIDS. 2023;37:1187-1188.
    >> Share

  45. ZACCARELLI M, Niyongabo B, Conway B
    Point-of-care urine tenofovir testing: making a good thing better.
    AIDS. 2023;37:1159-1160.
    >> Share

    May 2023
  46. KUHN L, Wang T, Li F, Strehlau R, et al
    Microbiota in the oral cavity of school-age children living with HIV who started antiretroviral therapy at young ages in South Africa.
    AIDS. 2023 May 12. doi: 10.1097/QAD.0000000000003599.
    >> Share

  47. AUGELLO M, Bono V, Rovito R, Tincati C, et al
    Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection.
    AIDS. 2023 May 5. doi: 10.1097/QAD.0000000000003585.
    >> Share


  48. Real world use of dolutegravir two drug regimens: Erratum.
    AIDS. 2023;37:1019.
    >> Share

  49. GUARALDI G, Milic J
    Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?
    AIDS. 2023;37:1005-1008.
    >> Share

    April 2023
  50. MARTYN-DICKENS C, Ojewale O, Sly-Moore E, Dompreh A, et al
    Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg.
    AIDS. 2023 Apr 14. doi: 10.1097/QAD.0000000000003576.
    >> Share


  51. Effect of antiretroviral therapy care interruptions on mortality in children living with HIV: Erratum.
    AIDS. 2023;37:859.
    >> Share

    March 2023
  52. STERMAN FL, Lalezari JP, Kowalczyk UM, Main DW, et al
    Bictegravir/Emtricitabine/Tenofovir Alafenamide Plus Doravirine in Highly Treatment-Experienced Men With Multidrug-Resistant HIV.
    AIDS. 2023 Mar 6. doi: 10.1097/QAD.0000000000003513.
    >> Share

  53. SHEN M, Xiao Y, Rong L, Zhuang G, et al
    The impact of attrition on the transmission of HIV and drug resistance: A mathematical modelling study.
    AIDS. 2023 Mar 6. doi: 10.1097/QAD.0000000000003528.
    >> Share

  54. FICHTENBAUM CJ, Mallon P
    Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?
    AIDS. 2023;37:541-543.
    >> Share

  55. PATTEN GE, Euvrard J, Anderegg N, Boulle A, et al
    Advanced HIV disease and engagement in care among patients on antiretroviral therapy in South Africa: results from a multi-state model.
    AIDS. 2023;37:513-522.
    >> Share

  56. PORTWOOD C, Sexton H, Kumarendran M, Brandon Z, et al
    Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy.
    AIDS. 2023;37:489-501.
    >> Share

  57. MONDESERT E, Reynes J, Makinson A, Bargnoux AS, et al
    Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy.
    AIDS. 2023;37:447-454.
    >> Share

  58. CASTILLO-ROZAS G, Lopez MN, Soto-Rifo R, Vidal R, et al
    Enteropathy and gut dysbiosis as obstacles to achieve immune recovery in undetectable people with HIV: a clinical view of evidence, successes, and projections.
    AIDS. 2023;37:367-378.
    >> Share

    February 2023
  59. MCCLUSKEY SM, Govender K, Adamson J, Gandhi M, et al
    Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
    AIDS. 2023 Feb 17. doi: 10.1097/QAD.0000000000003520.
    >> Share

  60. DE CASTRO N, Chazallon C, Brites C, Messou E, et al
    Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high-TB burden countries.
    AIDS. 2023 Feb 17. doi: 10.1097/QAD.0000000000003521.
    >> Share

  61. ZINO L, Jacobs TG, Nieuwenstein T, Grintjes K, et al
    Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report.
    AIDS. 2023;37:363-365.
    >> Share

  62. HANTTU AM, Pekkala S, Satokari R, Hartikainen AK, et al
    Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.
    AIDS. 2023;37:323-332.
    >> Share

    January 2023
  63. BOWMAN C, Ambrose A, Kanitkar T, Flores K, et al
    Real world use of dolutegravir two drug regimens.
    AIDS. 2023 Jan 16. doi: 10.1097/QAD.0000000000003480.
    >> Share

    December 2022
  64. HORNER MJ, Hazra R, Barnholtz-Sloan JS, Shiels MS, et al
    Cancer risk among HIV-exposed uninfected children in the United States.
    AIDS. 2022 Dec 23. doi: 10.1097/QAD.0000000000003458.
    >> Share

  65. PERNA A, Carleo MA, Mascolo S, Guida A, et al
    Adipocyte differentiation of 3T3-L1 cells under TAF, TDF and INSTIs selective challenge: an in vitro model.
    AIDS. 2022 Dec 13. doi: 10.1097/QAD.0000000000003455.
    >> Share

  66. BARCHI V, Rindi LV, Iannazzo R, Massa B, et al
    Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
    AIDS. 2022;36:2231-2233.
    >> Share

  67. DEL AMO J, Polo R, Moreno S, Martinez E, et al
    Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
    AIDS. 2022;36:2171-2179.
    >> Share

    November 2022
  68. VAN ZYL G, Jennings L, Kellermann T, Nkantsu Z, et al
    Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
    AIDS. 2022;36:2057-2062.
    >> Share

  69. MILNE RS, Beck IA, Levine M, So I, et al
    Low-frequency pre-treatment HIV drug resistance: effects on 2-year outcome of first-line efavirenz-based antiretroviral therapy.
    AIDS. 2022;36:1949-1958.
    >> Share

  70. RATHORE U
    Mitochondrial dysfunction in people with HIV receiving contemporary antiretroviral therapy.
    AIDS. 2022;36:2063-2064.
    >> Share

  71. LUMU I, Musaazi J, Castelnuovo B
    Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
    AIDS. 2022;36:1791-1800.
    >> Share

    October 2022
  72. DICKSON S, Gabriel N, Hernandez I
    Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.
    AIDS. 2022 Oct 7. pii: 00002030-990000000-00122.
    >> Share

    September 2022
  73. LUBEGA J, Kim TO, Airewele G, Grimes A, et al
    Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on anti-retrovirus therapy.
    AIDS. 2022 Sep 20. pii: 00002030-990000000-00116.
    >> Share

  74. YOUNGPAIROJ AS, Vanderford TH, Reed MS, Granade TC, et al
    A monoclonal antibody for the detection of the antiretroviral drug emtricitabine.
    AIDS. 2022 Sep 16. pii: 00002030-990000000-00092.
    >> Share

  75. LONDERO A, Fusi M, Cinausero M, Tascini C, et al
    Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
    AIDS. 2022;36:1603-1605.
    >> Share

  76. LUBEGA J, Grimes A, Airewele G, Bulsara S, et al
    Risk factors and prognostic significance of anemia in children with hiv infection on anti-retroviral therap.
    AIDS. 2022 Sep 1. pii: 00002030-990000000-00106.
    >> Share

    August 2022
  77. JASCHINSKI N, Greenberg L, Neesgaard B, Miro JM, et al
    Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV.
    AIDS. 2022 Aug 24. pii: 00002030-990000000-00102.
    >> Share

  78. AJAYKUMAR A, Caloren LC, Povshedna T, Hsieh AYY, et al
    Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and PBMC.
    AIDS. 2022 Aug 24. pii: 00002030-990000000-00104.
    >> Share

  79. THEERASUWIPAKORN N, Rungpradubvong V, Chattranukulchai P, Siwamogsatham S, et al
    Higher prevalence of QTc interval prolongation among virologically suppressed older people living with HIV.
    AIDS. 2022 Aug 16. pii: 00002030-990000000-00090.
    >> Share

  80. LAKE JE, Wang R, Barrett BW, Bowman E, et al
    Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.
    AIDS. 2022 Aug 11. pii: 00002030-990000000-00081.
    >> Share

  81. STAPLETON JT, Bedimo RJ, Guaraldi G
    Switch back from TAF to TDF or rather switch forward from metabolic toxicities of drugs to metabolic health of people living with HIV.
    AIDS. 2022;36:1457-1459.
    >> Share

    July 2022
  82. LI G, Park LS, Lodi S, Logan RW, et al
    Tenofovir disoproxil fumarate and COVID-19 outcomes in men with HIV.
    AIDS. 2022 Jul 15. pii: 00002030-990000000-00063.
    >> Share

  83. POLI G, Stapleton JT
    Sex matters... cytokines and disease progression in men and women receiving combination antiretroviral therapy.
    AIDS. 2022;36:1307-1309.
    >> Share

  84. MICAN R, Grela AG, Cadinanos J, de Miguel R, et al
    Impact of Pre-Existing Nrti Resistance on the Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experience Patients: Real-World Data.
    AIDS. 2022 Jul 8. pii: 00002030-990000000-00052.
    >> Share

    June 2022
  85. KAUPPINEN KJ, Aho I, Sutinen J
    Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
    AIDS. 2022 Jun 22. pii: 00002030-990000000-00035.
    >> Share

  86. HUNT M, Phillips R, Hardy Y, Owusu DO, et al
    Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV.
    AIDS. 2022;36:1049-1051.
    >> Share

  87. POST FA, Sinxadi P
    Tenofovir disoproxil and renal mitochondrial toxicity: more studies in Africans are needed.
    AIDS. 2022;36:1047-1048.
    >> Share

  88. JIANG W, Ronen K, Osborn L, Drake AL, et al
    Predictors of adverse pregnancy outcomes among Kenyan women with HIV on antiretroviral treatment in pregnancy.
    AIDS. 2022;36:1007-1019.
    >> Share

    May 2022
  89. PORTWOOD C, Sexton H, Kumarendran M, Brandon Z, et al
    Adverse perinatal outcomes associated with HAART and monotherapy: systematic review and meta-analysis.
    AIDS. 2022 May 24. pii: 00002030-990000000-00018.
    >> Share

  90. GIOVENCO D, Pettifor A, Powers KA, Hightow-Weidman L, et al
    Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women.
    AIDS. 2022 May 17. pii: 00002030-990000000-00015.
    >> Share

    April 2022
  91. SAX PE, Andreatta K, Molina JM, Daar ES, et al
    High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
    AIDS. 2022 Apr 23. pii: 00002030-990000000-00011.
    >> Share

    March 2022
  92. LEPIK KJ, Wang L, Harris M, Mclinden T, et al
    Evolving patterns of antiretroviral drug interactions in people living with HIV in British Columbia, Canada.
    AIDS. 2022 Mar 11. pii: 00002030-990000000-00005.
    >> Share

    February 2022
  93. FLETCHER CV, Kroon E, Schacker T, Pinyakorn S, et al
    Persistent HIV transcription and Variable ARV penetration in lymph nodes during plasma viral suppression.
    AIDS. 2022 Feb 18. pii: 00002030-900000000-96213.
    >> Share

  94. HAWKINS C, Kang M, Bhattacharya D, Cloherty G, et al
    Hepatitis B surface antigen and Hepatitis B RNA changes in HIV/HBV Co-infected participants receiving HBV-active antiretroviral therapy for 144 weeks.
    AIDS. 2022 Feb 14. pii: 00002030-900000000-96218.
    >> Share

  95. WANJALLA CN, Temu TM, Mashayekhi M, Warren CM, et al
    IL-17A is associated with flow-mediated dilation and IL-4 with carotid plaque in persons with HIV.
    AIDS. 2022 Feb 14. pii: 00002030-900000000-96217.
    >> Share

  96. JENNINGS L, Robbins RN, Nguyen N, Ferraris C, et al
    Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in south africa.
    AIDS. 2022 Feb 8. pii: 00002030-900000000-96225.
    >> Share

  97. MURDOCH IG, Jacobs TG, Nieuwenhuize RM, van Rossum-Schornagel QC, et al
    Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?
    AIDS. 2022;36:322-323.
    >> Share

  98. GUANIRA JV, Fichtenbaum CJ
    Is it time to retire efavirenz as a first-line option worldwide?
    AIDS. 2022;36:317-318.
    >> Share

  99. LU H, Cole SR, Westreich D, Hudgens MG, et al
    Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.
    AIDS. 2022;36:277-286.
    >> Share

  100. HERMANS LE, Hofstra LM, Schuurman R, Ter Heine R, et al
    HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment - week 96 results from the ITREMA trial.
    AIDS. 2022 Feb 1. pii: 00002030-900000000-96229.
    >> Share

  101. LACHATRE M, Pasquet A, Ajana F, Soudan B, et al
    Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective cART.
    AIDS. 2022 Feb 1. pii: 00002030-900000000-96227.
    >> Share

    January 2022
  102. LI B, Zhang L, Liu Y, Xiao J, et al
    A novel prediction model to evaluate the probability of CD4/CD8 ratio restoration in HIV-infected individuals.
    AIDS. 2022 Jan 14. pii: 00002030-900000000-96239.
    >> Share

  103. NOVAK RM, Armon C, Battalora L, Buchacz K, et al
    Aging, trends in CD4/CD8 ratio and clinical outcomes with persistent HIV suppression in the HIV outpatient study (HOPS).
    AIDS. 2022 Jan 10. pii: 00002030-900000000-96237.
    >> Share

  104. CALZA L, Borderi M, Colangeli V, Miani T, et al
    Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
    AIDS. 2022;36:153-155.
    >> Share

    December 2021
  105. KINGWARA L, Inzaule SC, Momanyi L, Jordan MR, et al
    Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor based regimens in children and adolescents in Kenya.
    AIDS. 2021 Dec 17. pii: 00002030-900000000-96249.
    >> Share

  106. SHAH S, Pilkington V, Hill A
    Is tenofovir disoproxil fumarate associated with weight loss?
    AIDS. 2021;35.
    >> Share

  107. JAMIESON L, Serenata C, Makhubele L, Sokhela S, et al
    Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
    AIDS. 2021;35.
    >> Share

  108. MCCLUSKEY SM, Pepperrell T, Hill A, Venter WDF, et al
    Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.
    AIDS. 2021;35.
    >> Share

  109. PAPOT E, Kaplan R, Vitoria M, Polizzotto MN, et al
    Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective.
    AIDS. 2021;35.
    >> Share

  110. NIKANJAM M, Tran L, Chadwick EG, Bwakura-Dangarembizi M, et al
    Impact of CYP2B6 genotype, TB therapy and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
    AIDS. 2021 Dec 6. pii: 00002030-900000000-96261.
    >> Share

  111. DALLA-POZZA P, Hentzien M, Allavena C, Maindreville AD, et al
    Progressive multifocal leukoencephalopathy in patients with immuno-virological control and at least 6 months of combination antiretroviral therapy.
    AIDS. 2021 Dec 6. pii: 00002030-900000000-96259.
    >> Share

  112. CATTANEO D, Fusi M, Micheli V, Resnati C, et al
    Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
    AIDS. 2021;35:2551-2553.
    >> Share

  113. RICHART V, Fernandez I, de Lazzari E, Berrocal L, et al
    High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption.
    AIDS. 2021;35:2463-2468.
    >> Share

    November 2021
  114. PRESSIAT C, Toni TD, Treluyer JM, Yonaba C, et al
    High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.
    AIDS. 2021;35:2409-2410.
    >> Share

  115. BUKKEMS VE, Hidalgo-Tenorio C, Garcia C, van Hulzen AGW, et al
    First pharmacokinetic data of bictegravir in pregnant women living with HIV.
    AIDS. 2021;35:2405-2406.
    >> Share

  116. FOWLER MG, Aizire J, Sikorskii A, Atuhaire P, et al
    Growth deficits in antiretroviral and HIV exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months-of-age.
    AIDS. 2021 Nov 3. pii: 00002030-900000000-96277.
    >> Share

  117. FORD N, Crawford KW, Ameyan W
    Rapidly starting antiretroviral therapy to improve outcomes among disadvantaged groups.
    AIDS. 2021;35:2217-2219.
    >> Share

    October 2021
  118. RONALD R, Gartland M, Li Z, Zhou N, et al
    Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
    AIDS. 2021 Oct 7. pii: 00002030-900000000-96298.
    >> Share

  119. NACCARATO M, Kwee F, Zaltzman J, Fong IW, et al
    Ritonavir-boosted antiretroviral therapy precipitating tacrolimus toxicity in a renal transplant patient: is it time for a priori tacrolimus dosage reduction?
    AIDS. 2021;35:2065-2068.
    >> Share

  120. BOZZI G, Meneri M, Peri AM, Taramasso L, et al
    Starting HIV therapy in patients with mitochondrial disease.
    AIDS. 2021;35:2063-2065.
    >> Share

    September 2021
  121. CAHN P, Madero JS, Arribas JR, Antinori A, et al
    Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection.
    AIDS. 2021 Sep 15. pii: 00002030-900000000-96314.
    >> Share

  122. QU Y, Weinstein A, Wang Z, Cheng Y, et al
    Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy.
    AIDS. 2021 Sep 13. pii: 00002030-900000000-96316.
    >> Share

  123. YAGER JL, Brooks KM, Castillo-Mancilla JR, Nemkov C, et al
    Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium, and high adherence to F/TAF vs. F/TDF.
    AIDS. 2021 Sep 2. pii: 00002030-900000000-96319.
    >> Share

    August 2021
  124. MICAN R, Busca Arenzana C, Vasquez J, Daroca G, et al
    Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
    AIDS. 2021;35:1707-1708.
    >> Share

  125. PASTICCI MB, De Socio GV, Gagliardini R, Merlini E, et al
    Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse.
    AIDS. 2021;35:1708-1710.
    >> Share

    July 2021
  126. DRAK D, Mcmanus H, Vickers T, Heron JE, et al
    Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort.
    AIDS. 2021 Jul 22. pii: 00002030-900000000-96341.
    >> Share

  127. MARUKUTIRA T, Wood BR
    Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
    AIDS. 2021;35:1505-1507.
    >> Share

  128. TAN CS, Reeves RK
    HIV on the brain: is neurosignalling damage irreversible even on antiretroviral therapy?
    AIDS. 2021;35:1503-1504.
    >> Share

  129. ASIF S, Baxevanidi E, Hill A, Venter F, et al
    The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV.
    AIDS. 2021 Jul 9. pii: 00002030-900000000-96351.
    >> Share

  130. WOOD BR, Pozniak AL
    Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!
    AIDS. 2021;35:1305-1307.
    >> Share

  131. DASH PK, Boix V
    Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns.
    AIDS. 2021;35:1301-1303.
    >> Share

  132. VELDSMAN KA, Laughton B, Janse van Rensburg A, Zuidewind P, et al
    Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age.
    AIDS. 2021;35:1247-1252.
    >> Share

  133. MOMPER JD, Wang J, Stek A, Shapiro DE, et al
    Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
    AIDS. 2021;35:1191-1199.
    >> Share

  134. MWASAKIFWA GE, Amin J, Kelleher A, Boyd MA, et al
    Inflammatory biomarker and soft tissue changes among patients commencing second-line ART after first-line virological failure.
    AIDS. 2021 Jul 1. pii: 00002030-900000000-96353.
    >> Share

    June 2021
  135. GILMORE JC, Zhang G, Cameron DW, Serghides L, et al
    Impact of in utero antiretroviral drug exposure on expression of membrane-associated transporters in mouse placenta and fetal brain.
    AIDS. 2021 Jun 25. pii: 00002030-900000000-96356.
    >> Share

  136. MORROW M, Mawhinney S, Coyle RP, Coleman SS, et al
    Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
    AIDS. 2021 Jun 14. pii: 00002030-900000000-96372.
    >> Share

  137. SHEN Y, Shiau S, Strehlau R, Burke M, et al
    Persistently lower bone mass and bone turnover among south african children living with well-controlled HIV.
    AIDS. 2021 Jun 14. pii: 00002030-900000000-96369.
    >> Share

  138. NWOGU JN, Gandhi M, Owen A, Khoo S, et al
    Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.
    AIDS. 2021 Jun 9. pii: 00002030-900000000-96381.
    >> Share

  139. ROLLE CP, Berhe M, Singh T, Ortiz R, et al
    Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
    AIDS. 2021 Jun 9. pii: 00002030-900000000-96380.
    >> Share

    May 2021
  140. BADE AN, Gendelman HE, McMillan J, Liu Y, et al
    Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue.
    AIDS. 2021 May 27. pii: 00002030-900000000-96396.
    >> Share

  141. VAN DEN ELSHOUT MAM, Hoornenborg E, Achterbergh RCA, Coyer L, et al
    Improving adherence to daily PrEP among MSM in Amsterdam by providing feedback via a mobile application.
    AIDS. 2021 May 17. pii: 00002030-900000000-96403.
    >> Share

  142. HAMADY A, Cooke GS, Garvey LJ
    Identification of hepatitis delta superinfection when investigating transaminitis in HIV/HBV coinfection.
    AIDS. 2021 May 10. pii: 00002030-900000000-96410.
    >> Share

  143. KEENE CM, Griesel R, Zhao Y, Gcwabe Z, et al
    Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line in adults failing a tenofovir-based first-line regimen: a prospective cohort study.
    AIDS. 2021 May 10. pii: 00002030-900000000-96409.
    >> Share

  144. ROYSTON L, Isnard S, Calmy A, Routy JP, et al
    Kaposi sarcoma in ART-treated people living with HIV: A wake-up call for research on HHV-8.
    AIDS. 2021 May 5. pii: 00002030-900000000-96414.
    >> Share

    April 2021
  145. MCCANN K, Shah S, Hindley L, Hill A, et al
    Implications of weight gain with newer antiretrovirals: 10-year predictions of cardiovascular disease and diabetes.
    AIDS. 2021 Apr 28. pii: 00002030-900000000-96415.
    >> Share

  146. SANDAMANN L, Stoll M, Behrens GMN
    Hypophosphatemia in people living with HIV: No benefit when switching from TDF to TAF.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96435.
    >> Share

  147. SEKABIRA R, Mcgowan I, Yuhas K, Brand RM, et al
    Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96434.
    >> Share

  148. GIANOTTI N, Galli L, Poli A, Torre LD, et al
    Residual viremia in HIV-infected patients who continue a 2-drug or switch to a 3-drug integrase strand transfer inhibitor-based regimen.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96432.
    >> Share

  149. BASTARD JP, Pelloux V, Alili R, Fellahi S, et al
    Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96429.
    >> Share

  150. APORNPONG T, Grinsztejn B, Hughes M, Ritz J, et al
    Antiretroviral Hair Levels, Self-Reported Adherence and Virologic Failure in Second-Line Regimen Patients in Resource-Limited Settings.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96428.
    >> Share

  151. MACBRAYNE CE, Rutstein RM, Wiznia AA, Graham B, et al
    Etravirine in treatment-experienced HIV-1 infected children 1-<6 years of age.
    AIDS. 2021 Apr 6. pii: 00002030-900000000-96427.
    >> Share

  152. FEINSTEIN MJ, Haberlen SA, Ashikaga H, Palella FJ, et al
    Ventricular ectopy and arrhythmia by HIV serostatus, viremia, and CD4+ cell count.
    AIDS. 2021;35:846-849.
    >> Share

  153. DRAK D, Dahwa R, Reakes E, Heron JE, et al
    Baseline renal function predicts mortality in adolescents commenced on HIV antiretroviral therapy.
    AIDS. 2021;35:843-845.
    >> Share

    March 2021
  154. LIN SH, Wang Y, Hartley SW, Karyadi DM, et al
    In utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newborns.
    AIDS. 2021 Mar 22. pii: 00002030-900000000-96446.
    >> Share

  155. METSU D, Aquilina C, Delobel P, Gandia P, et al
    Maraviroc exposure is influenced by exogenous thyrotoxicosis.
    AIDS. 2021;35:701-703.
    >> Share

  156. THIMM MA, Eke AC
    Tenofovir, pregnancy and renal function changes in pregnant women living with HIV.
    AIDS. 2021 Mar 11. pii: 00002030-900000000-96471.
    >> Share

  157. DEJONG C, Spinelli MA, Okochi H, Gandhi M, et al
    Tenofovir-based PrEP for COVID-19: an untapped opportunity?
    AIDS. 2021 Mar 11. pii: 00002030-900000000-96470.
    >> Share

  158. NICKOLAS TL, Barasch J, Mugwanya KK, Branch AD, et al
    Kidney injury biomarkers during exposure to tenofovir-based pre-exposure prophylaxis.
    AIDS. 2021 Mar 11. pii: 00002030-900000000-96467.
    >> Share

  159. MOUNZER K, Brunet L, Wyatt CM, Fusco JS, et al
    To dose-adjust or not to dose-adjust: 3TC dose in kidney impairment.
    AIDS. 2021 Mar 10. pii: 00002030-900000000-96461.
    >> Share

  160. CATTANEO D, Vinti P, Baldelli S, Fusi M, et al
    Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP.
    AIDS. 2021;35:522-524.
    >> Share

    February 2021
  161. NELSON M, Winston A, Hill A, Mngqibisa R, et al
    Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.
    AIDS. 2021 Feb 9. pii: 00002030-900000000-96482.
    >> Share

  162. FALADE-NWULIA O, Seaberg EC, Snider AE, Rinaldo CR, et al
    Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.
    AIDS. 2021 Feb 9. pii: 00002030-900000000-96487.
    >> Share

  163. MELLOR MM, Bast AC, Jones NR, Roberts NW, et al
    Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis.
    AIDS. 2021 Feb 3. pii: 00002030-900000000-96494.
    >> Share

  164. HAMZAH L, Post FA
    Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
    AIDS. 2021;35:349-351.
    >> Share

  165. CAZZANIGA A, Scrimieri R, Galli M, Maier J, et al
    Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
    AIDS. 2021;35:213-218.
    >> Share

    January 2021
  166. BYONANEBYE DM
    Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
    AIDS. 2021 Jan 13. pii: 00002030-900000000-96508.
    >> Share

    December 2020
  167. WOOD BR
    Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy.
    AIDS. 2020;34:2319-2320.
    >> Share

    November 2020
  168. ROSEBUSH JC, Best BM, Chadwick EG, Butler K, et al
    Pharmacokinetics and safety of maraviroc in neonates.
    AIDS. 2020 Nov 26. doi: 10.1097/QAD.0000000000002762.
    >> Share

  169. TREVILLYAN JM, Dart A, Paul E, Cavassini M, et al
    Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk; a randomised, controlled trial.
    AIDS. 2020 Nov 26. doi: 10.1097/QAD.0000000000002764.
    >> Share

  170. BROOKS KM, Momper JD, Pinilla M, Stek AM, et al
    Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s.
    AIDS. 2020 Nov 25. doi: 10.1097/QAD.0000000000002767.
    >> Share

  171. ERLANDSON KM, Wu K, Lake JE, Samuels DC, et al
    Mitochondrial DNA haplogroups and weight gain following switch to INSTI-Based ART.
    AIDS. 2020 Nov 25. doi: 10.1097/QAD.0000000000002771.
    >> Share

  172. REIN SM, Lampe FC, Johnson MA, Bhagani S, et al
    All-cause hospitalisation according to demographic group in people living with HIV in the current ART era: Recent findings from a cohort study in the UK.
    AIDS. 2020 Nov 9. doi: 10.1097/QAD.0000000000002750.
    >> Share

  173. ADAMS JW, Khan MR, Bessey SE, Friedman SR, et al
    Pre-exposure prophylaxis (PrEP) strategies for African American Women Affected by Mass Incarceration: A Modeling Study.
    AIDS. 2020 Nov 9. doi: 10.1097/QAD.0000000000002749.
    >> Share

  174. ROELOFSEN EE, Wildenbeest S, Mollema FP, Burger DM, et al
    Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
    AIDS. 2020;34:1989-1991.
    >> Share

  175. PYRA M, Rusie L, Castro M, Keglovitz Baker K, et al
    A taxonomy of pragmatic measures of HIV preexposure prophylaxis use.
    AIDS. 2020;34:1951-1957.
    >> Share

    October 2020
  176. CHANDIWANA NC, Chersich M, Venter WF, Akpomiemie G, et al
    Unexpected interactions between dolutegravir and folate: randomised trial evidence from South Africa.
    AIDS. 2020 Oct 20. doi: 10.1097/QAD.0000000000002741.
    >> Share

  177. CHLOE O, Elion R, Thompson M, Rockstroh JK, et al
    Changes in weight and body mass index with first-line doravirine-based therapy: a pooled analysis of three randomized controlled trials.
    AIDS. 2020 Oct 13. doi: 10.1097/QAD.0000000000002725.
    >> Share

  178. PINTYE J, Huo Y, Kacanek D, Zhang K, et al
    Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States.
    AIDS. 2020 Oct 12. doi: 10.1097/QAD.0000000000002730.
    >> Share

  179. BAJEMA KL, Nance RM, Delaney JAC, Eaton E, et al
    Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.
    AIDS. 2020 Oct 12. doi: 10.1097/QAD.0000000000002679.
    >> Share

  180. SIBIUDE J, Le Chenadec J, Mandelbrot L, Dollfus C, et al
    Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
    AIDS. 2020 Oct 8. doi: 10.1097/QAD.0000000000002719.
    >> Share

  181. HSU R, Brunet L, Fusco JS, Mounzer K, et al
    Incident Type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs.
    AIDS. 2020 Oct 8. doi: 10.1097/QAD.0000000000002718.
    >> Share

  182. PILKINGTON V, Hughes SL, Pepperrell T, McCann K, et al
    Tenofovir alafenamide versus tenofovir disoproxil fumarate - an updated meta-analysis of 14,894 patients across 14 trials.
    AIDS. 2020 Oct 8. doi: 10.1097/QAD.0000000000002699.
    >> Share

  183. SERRANO PA, Daubert E, Munoz A, Hosek SG, et al
    Effect of Truvada lawsuit advertising on PrEP attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.
    AIDS. 2020 Oct 6. doi: 10.1097/QAD.0000000000002728.
    >> Share

  184. CONWAY B
    Treatment of primary HIV infection: new data for a new era.
    AIDS. 2020;34:1855-1856.
    >> Share

  185. MAI B, Wang W, Lin M, Hu S, et al
    HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
    AIDS. 2020;34:1735-1743.
    >> Share

    September 2020
  186. YOTSUMOTO M, Hachiya A, Ichiki A, Amano K, et al
    Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    AIDS. 2020 Sep 14. doi: 10.1097/QAD.0000000000002688.
    >> Share

  187. BOUVIN-PLEY M, Leoz M, Roch E, Moreau A, et al
    Differential utilization of CD4 by transmitted/founder and chronic envelope glycoproteins in a MSM HIV-1 subtype B transmission cluster.
    AIDS. 2020 Sep 14. doi: 10.1097/QAD.0000000000002690.
    >> Share

  188. BANDA FM, Powis KM, Sun S, Makhema J, et al
    Fetal biometry following in utero exposure to dolutegravir- or efavirenz-based antiretroviral therapy.
    AIDS. 2020 Sep 8. doi: 10.1097/QAD.0000000000002674.
    >> Share

  189. AMBROSIONI J, Farrera J, de Lazzari E, Nicolas D, et al
    Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection.
    AIDS. 2020 Sep 8. doi: 10.1097/QAD.0000000000002685.
    >> Share

  190. MAHTAB S, Scott C, Asafu-Agyei NAA, Machemedze T, et al
    Prevalence and predictors of bone health among perinatally HIV-infected adolescents.
    AIDS. 2020 Sep 8. doi: 10.1097/QAD.0000000000002686.
    >> Share

  191. FEELEMYER J, Arasteh K, Thi HD, Hai OKT, et al
    Associations between methamphetamine use and lack of viral suppression among a cohort of HIV positive persons who inject drugs in hai phong vietnam.
    AIDS. 2020 Sep 8. doi: 10.1097/QAD.0000000000002680.
    >> Share

  192. BEDIMO RJ, Adams-Huet B, Nguyen V, Moore-Matthews D, et al
    Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
    AIDS. 2020;34:1687-1689.
    >> Share

  193. MOLINA-ITURRITZA E, San-Jose-Muniz I, Ganchegui-Aguirre M, Balerdi-Sarasola L, et al
    Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
    AIDS. 2020;34:1696-1697.
    >> Share

  194. SIRAPRAPASIRI T, Srithanaviboonchai K, Chantcharas P, Suwanphatthana N, et al
    Integration and scale-up of efforts to measure and reduce HIV-related stigma: the experience of Thailand.
    AIDS. 2020;34 Suppl 1:S103-S114.
    >> Share

  195. SINGH RJ, Sarna A, Schensul JJ, Mahapatra B, et al
    A multilevel intervention to reduce stigma among alcohol consuming men living with HIV receiving antiretroviral therapy: findings from a randomized control trial in India.
    AIDS. 2020;34 Suppl 1:S83-S92.
    >> Share

  196. GEIBEL S, Gottert A, Friedland BA, Jeremiah K, et al
    Internalized stigma among people living with HIV: assessing the Internalized AIDS-Related Stigma Scale in four countries.
    AIDS. 2020;34 Suppl 1:S33-S42.
    >> Share

  197. CHRISTOPOULOS KA, Neilands TB, Dilworth S, Lisha N, et al
    Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence.
    AIDS. 2020;34:1665-1671.
    >> Share

  198. DIRAJLAL-FARGO S, Yu J, Albar Z, Sattar A, et al
    Monocyte activation and gut barrier dysfunction in South African youth on antiretroviral therapy and their associations with endothelial dysfunction.
    AIDS. 2020;34:1615-1623.
    >> Share

  199. DHANDE JR, Saikia K, Singh DP, Bagul RD, et al
    Higher frequencies of functional HIV-envelope-specific memory B cells are associated with nonprogressive HIV infection in Indian population.
    AIDS. 2020;34:1603-1608.
    >> Share

    August 2020
  200. PINEIRO F, Climent F, Imaz A, Gudiol C, et al
    Clinical and pathological features of kaposi sarcoma herpesvirus inflammatory cytokine syndrome: case report and review of the literature.
    AIDS. 2020 Aug 10. doi: 10.1097/QAD.0000000000002669.
    >> Share

  201. BROCHADO-KITH O, Martinez I, Berenguer J, Medrano LM, et al
    Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study.
    AIDS. 2020 Aug 10. doi: 10.1097/QAD.0000000000002645.
    >> Share

  202. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Correlation of serum hepatitis B core-related antigen with HBV total intrahepatic DNA and ccc-DNA viral load in HIV-hepatitis B coinfection.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002659.
    >> Share

  203. GAY CL, Neo DT, Devanathan AS, Kuruc JD, et al
    Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002652.
    >> Share

  204. ASSOUMOU L, Racine C, Fellahi S, Lamaziere A, et al
    Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002644.
    >> Share

  205. REN M, Szadkowski L, Walmsley SL
    Deciphering the serological response to syphilis treatment in men living with HIV: do we meet the definitions for cure?
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002656.
    >> Share

  206. COUTIFARIS P, Byrd D, Childs J, Clark U, et al
    Neurobehavioral outcomes in young adults with perinatally-acquired HIV.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002655.
    >> Share

  207. STANGL AL, Pliakas T, Mainga T, Steinhaus M, et al
    The effect of universal testing and treatment on HIV stigma in 21 communities in Zambia and South Africa: results from a cluster randomised trial.
    AIDS. 2020 Aug 6. doi: 10.1097/QAD.0000000000002658.
    >> Share

  208. SU J, Shen X, Ni Q, Zhao H, et al
    Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
    AIDS. 2020;34:1575-1576.
    >> Share

    July 2020
  209. BOBROW K, Xia F, Hoang T, Valcour V, et al
    HIV and risk of dementia in older veterans.
    AIDS. 2020 Jul 22. doi: 10.1097/QAD.0000000000002597.
    >> Share

  210. TSHIVUILA-MATALA C, Honeyman S, Nesbitt C, Kirtley S, et al
    Perinatal outcomes associated with antiretroviral therapy: systematic review and network meta-analysis of randomised controlled trials.
    AIDS. 2020 Jul 21. doi: 10.1097/QAD.0000000000002593.
    >> Share

  211. PYRA M, Rusie L, Castro M, Baker KK, et al
    A taxonomy of pragmatic measures of HIV pre-exposure prophylaxis (PrEP) Use: application in a PrEP-using cohort in Chicago, IL.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002618.
    >> Share

  212. EGGERS C, Hoetelmans R, Laer S
    Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002626.
    >> Share

  213. FERRARA M, Bumpus NN, Ma Q, Ellis RJ, et al
    Antiretroviral drug concentrations in brain tissue of adult decedents.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002628.
    >> Share

  214. INZAULE SC, Jordan MR, Cournil A, Giron-Callejas A, et al
    Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low- and middle-income countries.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002623.
    >> Share

  215. LANG R, Czarnecki C, Kim J, Luider J, et al
    Identification and root-cause analysis of aberrant CD4 counts in an HIV cohort; the importance of quality control in changing laboratory procedure.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002638.
    >> Share

  216. ADACHI E, Saito M, Ikeuchi K, Hoshina T, et al
    Cases of coronavirus disease-2019 in HIV-infected transgender women.
    AIDS. 2020;34:1435-1436.
    >> Share

  217. ALUFANDIKA M, Lawrence DS, Boyer-Chammard T, Kanyama C, et al
    A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration.
    AIDS. 2020;34:1425-1428.
    >> Share

  218. SAMPAIO JDA, Jacome-Santos H, Aires AV, Pinheiro JJV, et al
    Orofacial outcomes in adolescents with perinatally infected HIV in antiretroviral therapy.
    AIDS. 2020;34:1417-1423.
    >> Share

  219. LIANG J, Nosova E, Reddon H, Nolan S, et al
    Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.
    AIDS. 2020;34:1389-1396.
    >> Share

  220. FEITERNA-SPERLING C, Bukkems VE, Teulen MJA, Colbers AP, et al
    Low raltegravir transfer into the breastmilk of a woman living with HIV.
    AIDS. 2020 Jul 14. doi: 10.1097/QAD.0000000000002624.
    >> Share

  221. COLEMAN H, Snell LB, Simons R, Douthwaite ST, et al
    Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV.
    AIDS. 2020;34:1258-1260.
    >> Share

  222. BRENNER BG
    Phylogenetics: an added ingredient in HIV prevention.
    AIDS. 2020;34:1247-1248.
    >> Share

  223. ODHIAMBO F, Mulwa E, Ayieko J, Kulzer J, et al
    Implementation of HIV care in Western Kenya during corona virus disease 2019 response.
    AIDS. 2020;34:F1-F2.
    >> Share

    June 2020
  224. BOUZIDI KEL, Jose S, Phillips AN, Pozniak A, et al
    First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study.
    AIDS. 2020 Jun 8. doi: 10.1097/QAD.0000000000002603.
    >> Share

  225. BROUILLETTE MJ, Fellows LK, Mayo NE
    Efavirenz and cognition that matters.
    AIDS. 2020;34:1105-1106.
    >> Share

  226. ASHIGBIE PG, Laing RO, Wirtz VJ, Nkrumah N, et al
    Registration timelines of antiretroviral medicines in Ghana and Kenya.
    AIDS. 2020;34:1093-1095.
    >> Share

    May 2020
  227. KABAMI J, Balzer LB, Saddiki H, Ayieko J, et al
    Population-level viral suppression among pregnant and postpartum women in a universal test and treat trial.
    AIDS. 2020 May 28. doi: 10.1097/QAD.0000000000002564.
    >> Share

  228. INZAULE SC, Jordan MR, Bello G, Wadonda-Kabondo N, et al
    High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly-diagnosed antiretroviral treatment naive children in sub-Saharan Africa.
    AIDS. 2020 May 20. doi: 10.1097/QAD.0000000000002580.
    >> Share

  229. CICCULLO A, Dusina A, Lassandro AP, Borghetti A, et al
    No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
    AIDS. 2020;34:956-957.
    >> Share

  230. TARAMASSO L, Berruti M, Briano F, Di Biagio A, et al
    The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    AIDS. 2020;34:877-881.
    >> Share

  231. WALMSLEY SL, Ren M, Simon C, Clarke R, et al
    Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults in Toronto, Canada.
    AIDS. 2020;34:859-867.
    >> Share

  232. GIANELLA S, Moser C, Vitomirov A, McKhann A, et al
    Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events.
    AIDS. 2020;34:849-857.
    >> Share

  233. LI Y, Altan E, Pilcher C, Hartogensis W, et al
    Semen virome of men with HIV on or off antiretroviral treatment.
    AIDS. 2020;34:827-832.
    >> Share

    April 2020
  234. CROWELL CS, Williams PL, Yildirim C, Van Dyke RB, et al
    Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected.
    AIDS. 2020 Apr 16. doi: 10.1097/QAD.0000000000002550.
    >> Share

  235. LACEY A, Savinelli S, Barco EA, Macken A, et al
    Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCDID Cohort.
    AIDS. 2020 Apr 16. doi: 10.1097/QAD.0000000000002541.
    >> Share

  236. PIGGOTT DA, Bandeen-Roche K, Mehta SH, Brown TT, et al
    Frailty transitions, inflammation and mortality among persons aging with HIV infection and injection drug use.
    AIDS. 2020 Apr 13. doi: 10.1097/QAD.0000000000002527.
    >> Share

  237. NASREDDINE R, Florence E, Vandercam B, Moutschen M, et al
    Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a belgian cohort of 4101 HIV patients.
    AIDS. 2020 Apr 13. doi: 10.1097/QAD.0000000000002533.
    >> Share

  238. NJUGUNA I, Neary J, Mburu C, Black D, et al
    Clinic- and individual-level factors that influence HIV viral suppression in adolescents and young adults: a national survey in Kenya.
    AIDS. 2020 Apr 13. doi: 10.1097/QAD.0000000000002538.
    >> Share

  239. MCMANUS M, Karalius B, Patel K, Persaud D, et al
    Quantitative HIV-1 specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA concentrations.
    AIDS. 2020 Apr 13. doi: 10.1097/QAD.0000000000002525.
    >> Share

  240. FRIJTERS EM, Hermans LE, Wensing AMJ, Deville WLJM, et al
    Risk factors for loss to follow-up from antiretroviral therapy programmes in low- and middle-income countries: a systematic review and meta-analysis.
    AIDS. 2020 Apr 13. doi: 10.1097/QAD.0000000000002523.
    >> Share

  241. WANG X, Boffito M, Dickinson L, Bagkeris E, et al
    Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV.
    AIDS. 2020;34:790-793.
    >> Share

  242. COTUGNO N, Morrocchi E, Rinaldi S, Rocca S, et al
    Early antiretroviral therapy-treated perinatally HIV-infected seronegative children demonstrate distinct long-term persistence of HIV-specific T-cell and B-cell memory.
    AIDS. 2020;34:669-680.
    >> Share

    March 2020
  243. PANPRADIST N, Beck IA, Ruth PS, Avila-Rios S, et al
    Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    AIDS. 2020 Mar 19. doi: 10.1097/QAD.0000000000002524.
    >> Share

  244. BOZZI G, Squillace N, Peri AM, Muscatello A, et al
    Immunological failure in an HIV elite controller: possible role of indirect markers of inflammation and benefit of antiretroviral therapy.
    AIDS. 2020;34:646-647.
    >> Share

  245. ANGELOVICH TA, Trevillyan JM, Hoy JF, Wong ME, et al
    Monocytes from men living with HIV exhibit heightened atherogenic potential despite long-term viral suppression with antiretroviral therapy.
    AIDS. 2020;34:513-518.
    >> Share

  246. LAURENCE J, Elhadad S, Gostynska S, Yu Z, et al
    HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-beta1 and intervention via anti-oxidant pathways.
    AIDS. 2020 Mar 11. doi: 10.1097/QAD.0000000000002516.
    >> Share

    February 2020
  247. SHIPEOLU L, Sampsel K, Reeves A, Blaskovits F, et al
    HIV nonoccupational postexposure prophylaxis (nPEP) for sexual assault cases: a three-year investigation.
    AIDS. 2020 Feb 17. doi: 10.1097/QAD.0000000000002507.
    >> Share

  248. FIELDS JA, Swinton MK, Soontornniyomkij B, Carson A, et al
    Beta amyloid levels in CSF of HIV-infected people vary by exposure to antiretroviral therapy.
    AIDS. 2020 Feb 17. doi: 10.1097/QAD.0000000000002506.
    >> Share

  249. SALLEH NAM, Van Draanen J, Nosova E, Barrios R, et al
    Material security and adherence to antiretroviral therapy (ART) among HIV-positive people who use illicit drugs.
    AIDS. 2020 Feb 17. doi: 10.1097/QAD.0000000000002501.
    >> Share

  250. NISHIJIMA T, Inaba Y, Kawasaki Y, Tsukada K, et al
    Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan.
    AIDS. 2020 Feb 6. doi: 10.1097/QAD.0000000000002498.
    >> Share

  251. TARAMASSO L, Berruti M, Briano F, di Biagio A, et al
    The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen.
    AIDS. 2020 Feb 5. doi: 10.1097/QAD.0000000000002496.
    >> Share

  252. STADER F, Decosterd L, Stoeckle M, Cavassini M, et al
    Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study.
    AIDS. 2020 Feb 5. doi: 10.1097/QAD.0000000000002489.
    >> Share

  253. MCCAUSLAND MR, Lebron AC, Pilch-Cooper HA, Howell S, et al
    Toll-like receptor distribution in colonic epithelium and lamina propria is disrupted in HIV viremic, immune success and failure.
    AIDS. 2020 Feb 5. doi: 10.1097/QAD.0000000000002499.
    >> Share

  254. YANG CT, Toh HS, Liao CT, Kuo S, et al
    Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected population.
    AIDS. 2020 Feb 5. doi: 10.1097/QAD.0000000000002490.
    >> Share

  255. SIANGPHOE U, Archer KJ, Nguyen C, Lee KR, et al
    Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1 infected patients.
    AIDS. 2020 Feb 5. doi: 10.1097/QAD.0000000000002491.
    >> Share

  256. LIN KS, Win S, Nyein PP
    Drug-induced immune hemolytic anemia because of efavirenz: a case report.
    AIDS. 2020;34:326-328.
    >> Share


  257. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas.
    AIDS. 2020;34:277-289.
    >> Share

    January 2020
  258. WANG X, Boffito M, Dickinson L, Bagkeris E, et al
    Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.
    AIDS. 2020 Jan 30. doi: 10.1097/QAD.0000000000002479.
    >> Share

  259. PHILLIPS TK, Orrell C, Brittain K, Zerbe A, et al
    Measuring retention in HIV care: the impact of data sources and definitions using routine data in South Africa.
    AIDS. 2020 Jan 30. doi: 10.1097/QAD.0000000000002478.
    >> Share

  260. GIRON LB, Papasavvas E, Azzoni L, Yin X, et al
    Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint.
    AIDS. 2020 Jan 17. doi: 10.1097/QAD.0000000000002476.
    >> Share

  261. SHROUFI A, Van Cutsem G, Cambiano V, Bansi-Matharu L, et al
    HIV viral load algorithm: what are the needs in the field?: authors' response.
    AIDS. 2020;34:160-162.
    >> Share

    December 2019
  262. CARR M, Richardson R, Tong W, Bloch M, et al
    Switch from tenofovir DF to raltegravir is not associated with weight gain over 96 weeks.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002473.
    >> Share

  263. SALOU M, Butel C, Comlan AS, Konou AA, et al
    Challenges of scale-up to Dolutegravir based regimens in sub-Saharan Africa: a case study in Togo.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002470.
    >> Share

  264. ALBERT AYK, Elwood C, Wagner EC, Pakzad Z, et al
    Investigation of Factors Associated with Spontaneous Preterm Birth in Pregnant Women Living with HIV.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002464.
    >> Share

  265. ORKIN C, Eron JJ, Rockstroh J, Podzamczer D, et al
    Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    AIDS. 2019 Dec 10. doi: 10.1097/QAD.0000000000002463.
    >> Share

  266. ASCHER SB, Scherzer R, Estrella MM, Shigenaga J, et al
    HIV pre-exposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
    AIDS. 2019 Dec 2. doi: 10.1097/QAD.0000000000002456.
    >> Share

  267. BRICENO O, Chavez-Torres M, Peralta-Prado A, Garrido-Rogriguez D, et al
    Associations between recent thymic emigrants and CD4+ T cell recovery after short-term antiretroviral therapy initiation.
    AIDS. 2019 Dec 2. doi: 10.1097/QAD.0000000000002458.
    >> Share

  268. YOUNG PW, Zielinski-Gutierrez E, Wamicwe J, Mukui I, et al
    Use of viral load to improve survey estimates of known HIV-positive status and antiretroviral treatment coverage.
    AIDS. 2019 Dec 2. doi: 10.1097/QAD.0000000000002453.
    >> Share

  269. MCCRARY AW, Nyandiko W, Ellis AM, Chakraborty H, et al
    Early cardiac dysfunction in children and young adults with perinatally acquired HIV.
    AIDS. 2019 Dec 2. doi: 10.1097/QAD.0000000000002445.
    >> Share

  270. DEL PUENTE F, Pontali E, Torresin A, Cassola G, et al
    Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.
    AIDS. 2019;33:2446-2447.
    >> Share

  271. FEITERNA-SPERLING C, Kruger R, Amara A, Khoo S, et al
    Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman.
    AIDS. 2019;33:2443-2444.
    >> Share

  272. LAPOINTE HR, Harrigan PR
    Narrowing down the causes of failure of tenofovir (only) for preexposure prophylaxis.
    AIDS. 2019;33:2437-2438.
    >> Share

  273. VENKATESH KK, Farhad M, Fenton T, Moodley D, et al
    Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
    AIDS. 2019;33:2403-2413.
    >> Share

  274. MILINKOVIC A, Berger F, Arenas-Pinto A, Mauss S, et al
    Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
    AIDS. 2019;33:2387-2391.
    >> Share

  275. COUNCIL OD, Ruone S, Mock PA, Khalil G, et al
    HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis.
    AIDS. 2019;33:2299-2307.
    >> Share

  276. BARAKAT E, Oren NC, Vaysberg A
    Symptomatic cerebrospinal fluid HIV escape syndrome in a patient on highly active antiretroviral therapy and suppressed plasma viral load.
    AIDS. 2019;33:2444-2446.
    >> Share

  277. BREW BJ, Barnes SL
    The impact of HIV central nervous system persistence on pathogenesis.
    AIDS. 2019;33 Suppl 2:S113-S121.
    >> Share

  278. SPUDICH S, Peterson J, Fuchs D, Price RW, et al
    Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence.
    AIDS. 2019;33 Suppl 2:S135-S144.
    >> Share

  279. SPUDICH S, Clements JE
    HIV persistence in the central nervous system during antiretroviral therapy: evidence and implications.
    AIDS. 2019;33 Suppl 2:S103-S106.
    >> Share

  280. MAZZITELLI M, Milinkovic A, Pereira B, Palmer J, et al
    Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV.
    AIDS. 2019;33:2439-2441.
    >> Share

  281. MUPFUMI L, Moyo S, Shin SS, Wang Q, et al
    High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015.
    AIDS. 2019;33:2415-2422.
    >> Share

  282. KIM-CHANG JJ, Donovan K, Loop MS, Hong S, et al
    Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV.
    AIDS. 2019;33:2363-2374.
    >> Share

  283. PALELLA FJ, Hart R, Armon C, Tedaldi E, et al
    Non-AIDS comorbidity burden differs by sex, race, and insurance type in aging adults in HIV care.
    AIDS. 2019;33:2327-2335.
    >> Share

  284. ANDERSON AM, Perez-Santiago J, Zheng Z, Huang E, et al
    Better executive function is independently associated with full HIV suppression during combination therapy.
    AIDS. 2019;33:2309-2316.
    >> Share

  285. SAINZ T, Serrano-Villar S, Mann S, Ma ZM, et al
    Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy.
    AIDS. 2019;33:2289-2298.
    >> Share

  286. COSTINIUK CT, Jenabian MA
    Cannabinoids and inflammation: implications for people living with HIV.
    AIDS. 2019;33:2273-2288.
    >> Share

    November 2019
  287. VEIL R, Poizot-Martin I, Reynes J, Goujard C, et al
    Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
    AIDS. 2019 Nov 19. doi: 10.1097/QAD.0000000000002447.
    >> Share

  288. POIZOT-MARTIN I, Lions C, Cheret A, Rey D, et al
    Kaposi sarcoma in people living with HIV: incidence and associated factors in the French DAT'AIDS cohort between 2010 and 2015.
    AIDS. 2019 Nov 19. doi: 10.1097/QAD.0000000000002450.
    >> Share

  289. MEYERS T, Samson P, Acosta EP, Moye J, et al
    Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
    AIDS. 2019;33:2197-2203.
    >> Share

  290. DI BIAGIO A, Magnasco L, Cenderello G, Rizzardini G, et al
    Response to letter to the editor: switch to dolutegravir and unboosted atazanavir.
    AIDS. 2019;33:2263-2264.
    >> Share

  291. DUARTE F, Soares MA
    Simplified two-drug antiretroviral HIV treatment: novel data and expected impact.
    AIDS. 2019;33:2266-2268.
    >> Share

  292. CASTAGNA A
    Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.
    AIDS. 2019;33:2264-2266.
    >> Share

  293. WILLIAMS DW, Elahi S
    Profound immune consequences for young adults infected with HIV perinatally or during childhood: a cautionary tale regarding adherence to antiretroviral therapy.
    AIDS. 2019;33:2251-2252.
    >> Share

  294. HENRIQUEZ S, Lecuroux C, Bitu M, Avettand-Fenoel V, et al
    The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients.
    AIDS. 2019;33:2137-2147.
    >> Share

  295. HOFFMAN RM, Balakasi K, Bardon AR, Siwale Z, et al
    Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia.
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002435.
    >> Share

  296. MORANGUINHO I, Borrego P, Goncalves F, Gomes P, et al
    Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failing first-line antiretroviral therapy.
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002431.
    >> Share

  297. VIZCARRA P, Vivancos MJ, Perez-Elias MJ, Moreno A, et al
    Weight gain in people living with HIV switched to dual therapy: changes in body fat mass.
    AIDS. 2019 Nov 9. doi: 10.1097/QAD.0000000000002421.
    >> Share

  298. NDUAGUBA SO, Barner JC, Ford KH, Lawson KA, et al
    Association between quality of care indicators for HIV infection and healthcare resource utilization and costs.
    AIDS. 2019 Nov 9. doi: 10.1097/QAD.0000000000002418.
    >> Share

  299. TENORE SB, Avelino-Silva VI, Costa PR, Franco LM, et al
    Immune effects of Lactobacillus casei Shirota in treated HIV-infected patients with poor CD4+ T cell recovery: a randomized trial.
    AIDS. 2019 Nov 9. doi: 10.1097/QAD.0000000000002420.
    >> Share

  300. BRETON G, Laborde-Balen G, Guilavogui F, Karemangino S, et al
    HIV viral load algorithm, what are the needs in the field?
    AIDS. 2019 Nov 5. doi: 10.1097/QAD.0000000000002382.
    >> Share

  301. TEASDALE CA, Yuengling KA, Mutiti A, Arpadi S, et al
    Delays in fast track antiretroviral therapy initiation and reasons for not starting treatment among eligible children in Eastern Cape, South Africa.
    AIDS. 2019;33:2099-2101.
    >> Share

  302. BRENNAN AT, Berry KM, Rosen S, Stokes A, et al
    Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa.
    AIDS. 2019;33:2049-2059.
    >> Share

    October 2019
  303. SUTCLIFFE CG, Drogt CS, van Dijk JH, Hamangaba F, et al
    Timing of and factors associated with HIV disclosure among perinatally infected children in rural Zambia.
    AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002411.
    >> Share

  304. GANDHI M, Wang G, King R, Rodrigues WC, et al
    Development and Validation of the First Point-of-Care Assay to Objectively Monitor Adherence to HIV Treatment and Prevention in Real-Time in Routine Settings.
    AIDS. 2019 Oct 11. doi: 10.1097/QAD.0000000000002395.
    >> Share

  305. COUNCIL OD, Ruone S, Mock PA, Khalil G, et al
    HIV-1 genetic diversity to estimate time of infection and infer adherence to pre-exposure prophylaxis.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002390.
    >> Share

  306. FOGEL JM, Sivay MV, Cummings V, Wilson EA, et al
    HIV drug resistance in a cohort of HIV-infected men who have sex with men in the United States.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002394.
    >> Share

  307. HSU DC, Ma YF, Narwan A, Rahalkar S, et al
    Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002389.
    >> Share

    September 2019
  308. BURNS JE, Stirrup OT, Dunn D, Runcie-Unger I, et al
    No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
    AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002379.
    >> Share

  309. LAPADULA G, Bernasconi DP, Bai F, Foca E, et al
    Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances: Results from a randomized controlled trial.
    AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002377.
    >> Share

  310. MCHALE JV, Aviles MAR
    Brexit and UK citizens with HIV residing in Spain: A matter of public health.
    AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002376.
    >> Share

    August 2019
  311. PANTAZIS N, Papastamopoulos V, Paparizos V, Metallidis S, et al
    Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    AIDS. 2019;33:1645-1655.
    >> Share

  312. LE CN, Britto P, Brummel SS, Hoffman RM, et al
    Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared to men.
    AIDS. 2019 Aug 1. doi: 10.1097/QAD.0000000000002334.
    >> Share

    July 2019
  313. NEESGAARD B, Pelchen-Matthews A, Ryom L, Florence E, et al
    Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe.
    AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002320.
    >> Share

  314. FLEMING J, Mathews WC, Rutstein RM, Aberg J, et al
    Low level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.
    AIDS. 2019 Jul 10. doi: 10.1097/QAD.0000000000002306.
    >> Share

  315. SHARMA S, Schlusser KE, de la Torre P, Tambussi G, et al
    The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    AIDS. 2019;33:1335-1344.
    >> Share

    May 2019
  316. SAMARANI S, Abulkhir A, Amre D, Mehraj V, et al
    The anti-inflammatory IL-37/SIGIRR axis is functionally compromised in HIV infection.
    AIDS. 2019 May 29. doi: 10.1097/QAD.0000000000002271.
    >> Share

  317. GUARDO AC, Zarama A, Gonzalez T, Bargallo ME, et al
    Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.
    AIDS. 2019;33:965-972.
    >> Share

    April 2019
  318. ALESSANDRI-GRADT E, Unal G, Leoz M, Plantier JC, et al
    Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.
    AIDS. 2019 Apr 3. doi: 10.1097/QAD.0000000000002215.
    >> Share

    March 2019
  319. BANSI-MATHARU L, Loria GR, Cole SR, Mugerwa H, et al
    Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.
    AIDS. 2019 Mar 29. doi: 10.1097/QAD.0000000000002210.
    >> Share

  320. LING L, Wu T, To KKW, Cheung KW, et al
    Vedolizumab-mediated integrin alpha4beta7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.
    AIDS. 2019;33:F1-F12.
    >> Share

    February 2019
  321. STIKSRUD B, Aass HCD, Lorvik KB, Ueland T, et al
    Activated dendritic cells and monocytes in HIV immunological non-responders; HIV-induced IP-10 correlates with low future CD4 recovery.
    AIDS. 2019 Feb 14. doi: 10.1097/QAD.0000000000002173.
    >> Share

  322. CHAN MK, Goodall R, Judd A, Klein N, et al
    Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand.
    AIDS. 2019 Feb 7. doi: 10.1097/QAD.0000000000002172.
    >> Share

    January 2019
  323. CHAISSON LH, Semitala FC, Asege L, Mwebe S, et al
    Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy.
    AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002130.
    >> Share

  324. BRITTAIN K, Phillips TK, Zerbe A, Abrams EJ, et al
    Long-term effects of unintended pregnancy on antiretroviral therapy outcomes among South African women living with HIV.
    AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002139.
    >> Share

    December 2018
  325. GUHA D, Mukerji SS, Chettimada S, Misra V, et al
    CSF extracellular vesicles and neurofilament light protein as biomarkers of CNS injury in HIV-infected patients on antiretroviral therapy.
    AIDS. 2018 Dec 14. doi: 10.1097/QAD.0000000000002121.
    >> Share

    November 2018
  326. WANG R, Haberlen SA, Palella FJ Jr, Mugavero MJ, et al
    Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?
    AIDS. 2018;32:2547-2556.
    >> Share

    October 2018
  327. GOSSEZ M, Martin GE, Pace M, Ramjee G, et al
    Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002044.
    >> Share

  328. ROUL H, Mary-Krause M, Ghosn J, Delaugerre C, et al
    CD4 cell count recovery after combined antiretroviral therapy in the modern cART era.
    AIDS. 2018 Oct 4. doi: 10.1097/QAD.0000000000002010.
    >> Share

  329. FORD ES, Magaret AS, Spak CW, Selke S, et al
    Increase in HSV shedding at initiation of antiretroviral therapy (ART) and decrease in shedding over time on ART in HIV and HSV-2 infected persons.
    AIDS. 2018 Oct 4. doi: 10.1097/QAD.0000000000002002.
    >> Share

  330. LAUT KG, Shepherd L, Gottfredsson M, Sedlacek D, et al
    Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations.
    AIDS. 2018 Oct 4. doi: 10.1097/QAD.0000000000002035.
    >> Share

  331. ABRAMS EJ, Langwenya N, Gachuhi A, Zerbe A, et al
    Impact of universal ART for pregnant and postpartum women on ART uptake and retention.
    AIDS. 2018 Oct 4. doi: 10.1097/QAD.0000000000002027.
    >> Share

    August 2018
  332. SHIBOSKI CH, Yao TJ, Russell JS, Ryder MI, et al
    The association between oral disease and type of antiretroviral therapy among perinatally HIV-Infected youth.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001965.
    >> Share

  333. KROON E, Pham PT, Sirivichayakul S, Trichavaroj R, et al
    Transmission dynamics among participants initiating anti-retroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001956.
    >> Share

    June 2018
  334. SIMMS V, Rylance S, Bandason T, Dauya E, et al
    CD4 count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence.
    AIDS. 2018 Jun 20. doi: 10.1097/QAD.0000000000001905.
    >> Share

  335. DE NEVE JW, Karlsson O, Coetzee L, Schroder H, et al
    Antiretroviral therapy coverage associated with increased co-residence between elderly people and prime-age adults in Africa.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001917.
    >> Share

    May 2018
  336. LE ROUX S, Donald K, Brittain K, Phillips TK, et al
    Neurodevelopment of breastfed HIV-exposed uninfected and HIV-unexposed children in South Africa: a prospective cohort.
    AIDS. 2018 May 22. doi: 10.1097/QAD.0000000000001872.
    >> Share

  337. SERRANO A, El Haddad S, Moal F, Prazuck T, et al
    Dysregulation of apoptosis and autophagy gene expression in PBMCs of efficiently treated HIV-infected patients.
    AIDS. 2018 May 3. doi: 10.1097/QAD.0000000000001851.
    >> Share

    March 2018
  338. ABRAHAM AG, Zhang L, Calkins K, Tin A, et al
    Vitamin D status and immune function reconstitution in HIV-infected men initiating therapy in the Multicenter AIDS cohort study.
    AIDS. 2018 Mar 15. doi: 10.1097/QAD.0000000000001782.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016